Medically reviewed by Christopher Lee, MD Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) ...

Pulmonary embolism is a common cause of cardiovascular-associated morbidity and mortality. Although pulmonary embolism ...

Highlight box Key findings • The bibliometric analysis summarized the major areas and promising research directions on chronic thromboembolic pulmonary hypertension (CTEPH) over the past two decades.

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Back to Healio In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

A new program in the Central Valley is now offering much-needed treatments for patients suffering from an advanced form of lung disease called pulmonary ...